A controlled trial of dothiepin and placebo in treating benzodiazepine withdrawal symptoms
| Autor: | Stephen P. Tyrer, Brian Ferguson, Marian Michie, Cosmo Hallstrom, Stephen Cooper, Peter Tyrer, Richard Caplan, Paul Barczak |
|---|---|
| Rok vydání: | 1996 |
| Předmět: |
medicine.drug_class
Benzodiazepine dependence Antidepressive Agents Tricyclic Placebo Drug Administration Schedule law.invention 03 medical and health sciences Drug withdrawal Benzodiazepines 0302 clinical medicine Randomized controlled trial Double-Blind Method law Dothiepin Statistical significance medicine Ambulatory Care Humans 030212 general & internal medicine chemistry.chemical_classification Neurologic Examination Benzodiazepine Dose-Response Relationship Drug medicine.disease 030227 psychiatry Substance Withdrawal Syndrome Psychiatry and Mental health Treatment Outcome chemistry Anti-Anxiety Agents Patient Satisfaction Anesthesia Antidepressant Psychology Tricyclic |
| Zdroj: | The British journal of psychiatry : the journal of mental science. 168(4) |
| ISSN: | 0007-1250 |
| Popis: | BackgroundThe possibility that treatment with tricyclic antidepressants, in the form of dothiepin, might attenuate benzodiazepine withdrawal symptoms was investigated in a double-blind trial.MethodEighty-seven non-depressed psychiatric out-patients with putative normal dose benzodiazepine dependence had their benzodiazepines reduced in stepwise amounts of 20% of the original dose for eight weeks. The patients were randomised to receive dothiepin (with dosage increasing to 150 mg/day) or placebo as an aid to withdrawal before benzodiazepine reduction and these drugs were taken for four further weeks before being stopped.ResultsFewer patients entered and completed the study than expected and a Type II error was possible in the results. Although there was some evidence of withdrawal symptoms being less marked in those patients allocated to dothiepin this was independent of any antidepressant effect as depression scores were lower in the placebo group in the early phase of withdrawal (PP=0.03) was recorded by those who had received dothiepin; no other differences reached statistical significance.ConclusionsDothiepin (and by implication other tricyclic antidepressants) might have some value in reducing benzodiazepine withdrawal symptoms but does not aid drug withdrawal. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|